---

Advances in semiconductor technology and edge AI are pushing wearable biosensors far beyond simple fitness tracking. Yet despite rapid innovation, the industry still faces major hurdles in turning consumer wearables into clinically accepted healthcare tools, according to a new strategic outlook paper from the SEMI Smart MedTech Initiative.

The paper, Medicalizing Consumer Silicon, examines why many promising biosensor technologies struggle to move from wellness applications into large-scale clinical deployment. For eeNews Europe readers, the report offers insight into the growing role of semiconductor integration, signal quality and AI in healthcare devices, as well as the technical and regulatory challenges that must be overcome to unlock new medical markets.

Semiconductor integration remains a key barrier

According to SEMI, one of the biggest obstacles is not the performance of individual semiconductor components, but how effectively they are integrated into complete systems.

“Even with today’s accelerated innovation for individual semiconductor components, poor integration is a primary barrier inhibiting the device performance required for clinical acceptance,” said Gity Samadi, Senior Director, R&D Programs at SEMI. “The core technologies that measure biomarkers in both consumer and clinical tools are similar, but the biggest differences come down to validation requirements, intended use of the device, and regulatory context. Members of the SEMI Smart MedTech Initiative authored this paper to help mitigate today’s limited alignment across stakeholders, with the goal of improving integration to create wearables that are robust enough for use in real-world healthcare settings.”

The paper was developed with contributions from experts across the semiconductor, medical device, healthcare and academic sectors, including participants from Intel, GlobalFoundries, STMicroelectronics, Medtronic, Mayo Clinic and Purdue University.

Consumer devices versus clinical wearables

A key theme of the report is the gap between consumer-grade and clinical-grade biosensors. While smartwatches such as the Apple Watch and Samsung Galaxy Watch typically use single-lead ECG technology, FDA-cleared diagnostic wearables employ more sophisticated multi-lead ECG systems capable of generating higher-quality clinical data.

The report argues that technological capability alone is not enough. Clinical adoption is slowed by challenges including biosignal acquisition quality, software interoperability, AI integration, data privacy concerns and inconsistent regulatory frameworks. Human factors such as comfort and long-term user compliance also play a significant role.

“Effective use of wearable devices can provide key health insights, help with diagnosis, aid in treatment planning, and track treatment effectiveness and adherence,” said Bharath Rajagopalan, Director of Strategic Marketing at STMicroelectronics. “For this to be possible, data must be trusted, clear, and usable for clinical decision making. Because the effort to acquire actionable data and streamline regulatory frameworks spans multiple disciplines and industries, the SEMI Smart MedTech Initiative is working to convene key stakeholders to address the structural issues to enable reliable and scalable adoption.”

Collaboration needed for medical-grade wearables

SEMI concludes that stronger collaboration between industry, academia and government will be essential to address validation standards, cybersecurity, interoperability and regulatory alignment. The organization believes that overcoming these structural challenges could help accelerate the transition of wearable biosensors from consumer wellness products into trusted medical devices capable of supporting diagnosis and treatment in real-world healthcare environments.

---

---